Welcome to LookChem.com Sign In|Join Free
  • or
6,7-DIMETHOXY-1,4-DIHYDRO-3H-ISOCHROMEN-3-ONE is a chemical compound with the molecular formula C11H12O4, belonging to the isochromen-3-one derivatives. It features two methoxy (O-CH3) groups at the 6 and 7 positions, which contribute to its potential pharmacological and biological properties. 6,7-DIMETHOXY-1,4-DIHYDRO-3H-ISOCHROMEN-3-ONE has been studied for its antimicrobial and antioxidant activities, as well as its potential as a building block in the synthesis of organic compounds. Furthermore, research indicates that 6,7-DIMETHOXY-1,4-DIHYDRO-3H-ISOCHROMEN-3-ONE may possess anti-inflammatory and anti-tumor properties, making it a promising candidate for further exploration in medicinal chemistry and drug discovery.

16135-41-4

Post Buying Request

16135-41-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

16135-41-4 Usage

Uses

Used in Pharmaceutical Industry:
6,7-DIMETHOXY-1,4-DIHYDRO-3H-ISOCHROMEN-3-ONE is used as a potential therapeutic agent for its antimicrobial properties, offering a new avenue for the development of antibiotics to combat resistant bacteria.
Used in Cosmetic Industry:
6,7-DIMETHOXY-1,4-DIHYDRO-3H-ISOCHROMEN-3-ONE is used as an antioxidant ingredient in cosmetic products to protect the skin from oxidative stress and environmental damage, potentially reducing the signs of aging and promoting skin health.
Used in Organic Synthesis:
6,7-DIMETHOXY-1,4-DIHYDRO-3H-ISOCHROMEN-3-ONE serves as a valuable building block in the synthesis of various organic compounds, contributing to the development of new chemical entities with diverse applications in different industries.
Used in Antitumor Research:
6,7-DIMETHOXY-1,4-DIHYDRO-3H-ISOCHROMEN-3-ONE is used as a subject of study in anti-tumor research, with its potential anti-tumor properties making it a candidate for the development of novel cancer therapies.
Used in Anti-inflammatory Applications:
6,7-DIMETHOXY-1,4-DIHYDRO-3H-ISOCHROMEN-3-ONE is utilized in the investigation of its anti-inflammatory properties, which could lead to the creation of new treatments for inflammatory diseases.

Check Digit Verification of cas no

The CAS Registry Mumber 16135-41-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,1,3 and 5 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 16135-41:
(7*1)+(6*6)+(5*1)+(4*3)+(3*5)+(2*4)+(1*1)=84
84 % 10 = 4
So 16135-41-4 is a valid CAS Registry Number.
InChI:InChI=1/C11H12O4/c1-13-9-3-7-5-11(12)15-6-8(7)4-10(9)14-2/h3-4H,5-6H2,1-2H3

16135-41-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 6,7-dimethoxy-1,4-dihydroisochromen-3-one

1.2 Other means of identification

Product number -
Other names 6,7-dimethoxychroman-3-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:16135-41-4 SDS

16135-41-4Relevant academic research and scientific papers

New MT2 melatonin receptor-selective ligands: Agonists and partial agonists

Boutin, Jean A.,Bonnaud, Anne,Brasseur, Chantal,Bruno, Olivier,Lepretre, Nolwenn,Oosting, Peter,Coumailleau, Sophie,Delagrange, Philippe,Nosjean, Olivier,Legros, Céline

, (2017/07/04)

The search for melatonin receptor agonists and antagonists specific towards one of the receptor subtypes will extend our understanding of the role of this system in relaying circadian information to the body. A series of compounds derived from a hit compound discovered in a screening process led to powerful agonists specific for one of the isoform of the melatonin receptor namely, MT2. The compounds are based on a poorly explored skeleton in the molecular pharmacology of melatonin. By changing the steric hindrance of one substituent (i.e., from a hydrogen atom to a tributylstannyl group), we identified a possible partial agonist that could lead to antagonist analogues. The functionalities of these compounds were measured with a series of assays, including the binding of GTPγS, the inhibition of the cyclic AMP production, the β-arrestin recruitment, and the cell shape changes as determined by cellular dielectric spectroscopy (CellKey). The variations between the compounds are discussed.

Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776)

Beck, Daniel E.,Agama, Keli,Marchand, Christophe,Chergui, Adel,Pommier, Yves,Cushman, Mark

, p. 1495 - 1512 (2014/03/21)

Carbohydrate moieties were strategically transported from the indolocarbazole topoisomerase I (Top1) inhibitor class to the indenoisoquinoline system in search of structurally novel and potent Top1 inhibitors. The syntheses and biological evaluation of 20 new indenoisoquinolines glycosylated with linear and cyclic sugar moieties are reported. Aromatic ring substitution with 2,3-dimethoxy-8,9-methylenedioxy or 3-nitro groups exerted strong effects on antiproliferative and Top1 inhibitory activities. While the length of the carbohydrate side chain clearly correlated with antiproliferative activity, the relationship between stereochemistry and biological activity was less clearly defined. Twelve of the new indenoisoquinolines exhibit Top1 inhibitory activity equal to or better than that of camptothecin. An advanced synthetic intermediate from this study was also used to efficiently prepare indotecan (LMP400) and indimitecan (LMP776), two anticancer agents currently under investigation in a Phase I clinical trial at the National Institutes of Health.

Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof

-

Page/Page column 16-17, (2010/02/08)

The invention concerns novel benzodiazepine derivatives and their uses in the field of therapeutics particularly for treating pathologies involving the activity of a cyclic nucleotide phosphodiesterase. It also concerns methods for preparing them and novel synthesis intermediates. The inventive compounds more particularly correspond to general formula (I):

Preparation of Novel 4-Substituted 6-Methoxy, 6,7-Dimethoxy-, and 6,7-(Methylenedioxy)isochroman-3-ones. 2

Khanapure, Subhash P.,Biehl, Edward R.

, p. 1471 - 1475 (2007/10/02)

The title compounds 20, 21, and 22 have been prepared in modest yields by a two-step reaction involving first the reaction of bromoarenes 3, 7, and 8 with lithioalkyl- and lithioarylacetonitriles under aryne-forming conditions.The cyano products 10, 14, and 16 so formed were then converted to the corresponding isochroman-3-ones by acidic hydrolysis.

STUDIES ON THE SYNTHESIS OF BENZOLACTAM RINGS. II SYNTHESIS OF 1,4-DIHYDRO-3(2H)-ISOQUINOLINONE DERIVATIVES

Kamochi, Yasuko,Watanabe, Yasuo

, p. 2385 - 2391 (2007/10/02)

A new synthesis of 1,4-dihydro-3(2H)-isoquinolinones by the amidomethylation with acrylacetamide or acrylacetonitrile and paraformaldehyde in some acid-catalysts is described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 16135-41-4